Physician profile
Scott C Behler
NPI 1285746891
$1,699.74
in general payments reported to CMS, 2019-2025
20 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $64.76 · 2021: $274 · 2022: $253 · 2023: $384 · 2024: $259 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.32 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $186.05 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $179.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $174.41 | 2023-2025 | Durysta |
| Novartis Pharmaceuticals Corporation | $164.04 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $163.35 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $152.14 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $124.67 | 2023-2025 | Tecnis Iol, Veritas Vision System |
| Dompe US, INC. | $95.70 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $83.93 | 2023 | Tepezza |
| Alcon Vision LLC | $79.88 | 2022-2025 | Rocklatan |
| Shire North American Group INC | $63.35 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $45.62 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.89 | 2020-2021 | |
| Ocular Therapeutix, INC. | $31.12 | 2021-2022 | |
| Biotissue Holdings INC. | $24.28 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $21.98 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.68 | 2021 | |
| Amgen INC. | $19.91 | 2025 | Tepezza |
| Rxsight INC | $19.38 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Allergan, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Behler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.